Welcome to our dedicated page for Averin Cap Acquisition news (Ticker: ACAAU), a resource for investors and traders seeking the latest updates and insights on Averin Cap Acquisition stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Averin Cap Acquisition's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Averin Cap Acquisition's position in the market.
Averin Capital Acquisition Corp (NASDAQ: ACAAU) completed a $250,000,000 initial public offering of 25,000,000 units at $10.00 per unit, with trading beginning February 19, 2026. Each unit equals one Class A ordinary share plus one-sixth of a redeemable warrant, exercisable at $11.50 per share.
The company granted a 45-day over-allotment option for 3,750,000 units and placed $2,000,000 in trust. Averin is a blank check company targeting technology and health sector combinations; registration was declared effective by the SEC on February 18, 2026.
Averin Capital Acquisition Corp (NASDAQ:ACAAU) priced a $250,000,000 initial public offering of 25,000,000 units at $10.00 per unit, expected to begin trading on Feb 19, 2026.
Each unit includes one Class A share and one-sixth of a warrant (whole warrant strike $11.50). $10.00 per unit will be deposited into a trust account. The offering is expected to close on Feb 20, 2026 and includes a 45-day option to sell an additional 3,750,000 units. The sponsor is a blank-check company targeting technology and health, led by David A. Berry and Alex Lau; Deutsche Bank is sole book-runner.